{
    "clinical_study": {
        "@rank": "163050", 
        "acronym": "MM", 
        "arm_group": [
            {
                "arm_group_label": "Subcutaneous", 
                "arm_group_type": "Experimental", 
                "description": "PAD regimen with subcutaneous bortezomib"
            }, 
            {
                "arm_group_label": "Intravenous", 
                "arm_group_type": "Active Comparator", 
                "description": "PAD regimen with intravenous bortezomib"
            }
        ], 
        "brief_summary": {
            "textblock": "Intravenous injection is the standard administration route of bortezomib; however,\n      subcutaneous administration is an important alternative. We want to compared the effi cacy\n      and safety of subcutaneous versus intravenous bortezomib at the approved 1\u20223 mg/m2 dose and\n      twice per week,on days1, 4, 8 and 11 of 21-day cycles, schedule in patients with multiple\n      myeloma. At the same time we adjust the dose of dexamethasone at 10mg and twice everyday, on\n      days 1, 2, 4, 5, 8, 9, 11 and 12."
        }, 
        "brief_title": "Improved PAD Regimen In Multiple Myeloma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma Proved by Laboratory Tests", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be Multiple Myeloma Proved by Laboratory Tests\n\n          -  Must have the ability to observe the efficacy and events\n\n          -  Patient must have the ability to understand and willingness to provide written\n             informed consent in the study and any related procedures being performed\n\n        Exclusion Criteria:\n\n          -  If have uncontrolled intercurrent illness including ongoing or active infection,heart\n             failure,unstable angina pectoris,or psychiatric illness/social situations that study\n             requirements\n\n          -  If have severe side-effects on bortezomib"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01812096", 
            "org_study_id": "chengchengfu"
        }, 
        "intervention": [
            {
                "arm_group_label": "Subcutaneous", 
                "intervention_name": "Subcutaneous  bortezomib", 
                "intervention_type": "Other", 
                "other_name": "the methods of use bortezomib"
            }, 
            {
                "arm_group_label": "Intravenous", 
                "intervention_name": "Intravenous bortezomib", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bortezomib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "multiple myeloma", 
            "bortezomib", 
            "Subcutaneous"
        ], 
        "lastchanged_date": "March 13, 2013", 
        "number_of_arms": "2", 
        "official_title": "Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China", 
        "overall_official": {
            "affiliation": "First Affiliated Hospital,Soochow University", 
            "last_name": "Fu chengcheng, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "overall survival rates", 
            "safety_issue": "Yes", 
            "time_frame": "three years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01812096"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "disease free survival", 
            "safety_issue": "Yes", 
            "time_frame": "three years"
        }, 
        "source": "The First Affiliated Hospital of Soochow University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The First Affiliated Hospital of Soochow University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}